Doron G. Hickey

Doron G. Hickey

Auto-generated profile, based on publicly available information

Doron G. Hickey

Royal Victorian Eye and Ear Hospital

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2021 in Clinical and Experimental Optometry
Verified
Journal Article
Closed access
MHMonica L Hu
Monica L Hu
TEThomas L Edwards
Thomas L Edwards
FOFleur O’hare
Fleur O’hare
DHDoron G Hickey
Doron G Hickey
Jiang-Hui WangJiang-Hui Wang
Jiang-Hui Wang
LALauren N Ayton
Lauren N Ayton
Inherited retinal diseases (IRDs) comprise a heterogeneous group of genetic disorders affecting the retina. Caused by mutations in over 300 genes, IRDs result in visual impairment due to dysfunction and degeneration of photoreceptors, retinal pigment epithelium, or the choroid. Important photoreceptor IRDs include retinitis pigmentosa and Leber congenital amaurosis. Macular dystrophies include Stargardt and Best disease. Currently, IRDs are largely incurable but the landscape of treatment options is rapidly changing for these diseases which, untreated, result in severe visual impairment and blindness. Advances in DNA delivery to the retina and improved genetic diagnosis of IRDs have led to a new era of research into gene therapy for these vision-threatening disorders. Gene therapy is a compelling approach due to the monogenic nature of most IRDs, with the retina being a favourable target for administering genetic vectors due to its immunoprivileged environment, direct visibility, and multiple methods to assess sensitivity and function. Generally, retinal gene therapy involves a subretinal or intravitreal injection of a viral vector, which infects target cells to deliver a therapeutic gene, or transgene. A gene augmentation strategy introduces a functioning copy of a gene to restore expression of a mutated gene, whereas a gene-editing strategy aims to directly edit and correct the mutation. Common delivery vectors include adeno-associated virus (AAV) and lentivirus. Voretigene neparvovec-rzyl (Luxturna) became the first FDA-approved direct gene therapy in December 2017, and the Australian TGA followed suit in August 2020. More are projected to follow, with clinical trials underway for many other IRDs. This review provides an overview of gene therapy for IRDs, including current progress and challenges. A companion article in this issue details target patient populations for IRD gene therapy, and how optometrists can assist in assessing individuals who may be eligible for current and future therapies.

16 September 2024 in Genome Research
Verified
Journal Article
Closed access
GAGocuk Sena A.
Gocuk Sena A.
JLJames Lancaster
James Lancaster
SSShian Su
Shian Su
JJJasleen K Jolly
Jasleen K Jolly
TEThomas L. Edwards
Thomas L. Edwards
QGQuentin Gouil
Quentin Gouil
X-linked genetic disorders typically affect females less severely than males owing to the presence of a second X Chromosome not carrying the deleterious variant. However, the phenotypic expression in females is highly variable, which may be explained by an allelic skew in X-Chromosome inactivation. Accurate measurement of X inactivation skew is crucial to understand and predict disease phenotype in carrier females, with prediction especially relevant for degenerative conditions. We propose a novel approach using nanopore sequencing to quantify skewed X inactivation accurately. By phasing sequence variants and methylation patterns, this single assay reveals the disease variant, X inactivation skew, and its directionality and is applicable to all patients and X-linked variants. Enrichment of X Chromosome reads through adaptive sampling enhances cost-efficiency. Our study includes a cohort of 16 X-linked variant carrier females affected by two X-linked inherited retinal diseases: choroideremia andRPGR-associated retinitis pigmentosa. As retinal DNA cannot be readily obtained, we instead determine the skew from peripheral samples (blood, saliva, and buccal mucosa) and correlate it to phenotypic outcomes. This reveals a strong correlation between X inactivation skew and disease presentation, confirming the value in performing this assay and its potential as a way to prioritize patients for early intervention, such as gene therapy currently in clinical trials for these conditions. Our method of assessing skewed X inactivation is applicable to all long-read genomic data sets, providing insights into disease risk and severity and aiding in the development of individualized strategies for X-linked variant carrier females.

14 July 2021 in Journal of Experimental Biology
Verified
Journal Article
Open access
PDF file
DHDoron G. Hickey
Doron G. Hickey
WDWayne I. L. Davies
Wayne I. L. Davies
SHSteven Hughes
Steven Hughes
JRJessica Rodgers
Jessica Rodgers
NTNavamayooran Thavanesan
Navamayooran Thavanesan
MHMark W Hankins
Mark W Hankins
Human opsin-based photopigments have great potential as light-sensitisers, but their requirement for phototransduction cascade-specific second messenger proteins may restrict their functionality in non-native cell types. In this study, eight chimeric human opsins were generated consisting of a backbone of either a rhodopsin (RHO) or long-wavelength-sensitive (LWS) opsin and intracellular domains from Gq/11-coupled human melanopsin. Rhodopsin/melanopsin chimeric opsins coupled to both Gi and Gq/11 pathways. Greater substitution of the intracellular surface with corresponding melanopsin domains generally showed greater Gq/11 activity with a decrease in Gi activation. Unlike melanopsin, rhodopsin and rhodopsin/melanopsin chimeras were dependent upon exogenous chromophore to function. By contrast, wild-type LWS opsin and LWS opsin/melanopsin chimeras showed only weak Gi activation in response to light, whilst Gq/11 pathway activation was not detected. Immunocytochemistry (ICC) demonstrated that chimeric opsins with more intracellular domains of melanopsin were less likely to be trafficked to the plasma membrane. This study demonstrates the importance of Gα coupling efficiency to the speed of cellular responses and created human opsins with a unique combination of properties to expand the range of customised optogenetic biotools for basic research and translational therapies.

1 March 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
ZLZhengyang Liu
Zhengyang Liu
LALauren N. Ayton
Lauren N. Ayton
FOFleur O'HAre
Fleur O'HAre
JAJanan Arslan
Janan Arslan
MHMonica L Hu
Monica L Hu
TEThomas L. Edwards
Thomas L. Edwards

15 September 2024 in Clinical and Experimental Optometry
Verified
Journal Article
Open access
PTParker Truong
Parker Truong
HMHeather Gwen MacK
Heather Gwen MacK
AMAndrew B Metha
Andrew B Metha
NDNelofar Deen
Nelofar Deen
DHDoron G Hickey
Doron G Hickey
LALauren N Ayton
Lauren N Ayton

25 February 2021 in Clinical and Experimental Optometry
Verified
Journal Article
Closed access
FOFleur O’hAre
Fleur O’hAre
TEThomas L Edwards
Thomas L Edwards
MHMonica L Hu
Monica L Hu
DHDoron G Hickey
Doron G Hickey
AZAlexis C Zhang
Alexis C Zhang
LALauren N Ayton
Lauren N Ayton
This review presents the phenotypic and genotypic profiles of a select group of inherited retinal diseases (IRDs) that are currently the focus of retinal gene therapy trials globally. Research progress in IRD treatment trials may soon lead to their availability in Australia and New Zealand, as either approved treatment or a clinical trial. The salient clinical characteristics of retinitis pigmentosa—the largest IRD category—are highlighted, with specific reference to RPE65-associated Leber congenital amaurosis, followed by other specific IRDs, namely choroideremia and ABCA4-associated Stargardt disease. These IRDs are selected based on their candidacy for gene therapy. Guidance on the clinical diagnostic tests that support each of these diagnoses will be presented. More broadly, the most useful structure and function measures to monitor IRD progression is discussed, along with the key assessments that offer differential diagnostic insight. This review is intended to be a clinical guide for optometrists, to assist in assessment and management of individuals who may be eligible for current and future gene therapies. A companion article in this issue will provide an overview of the basic principles of gene therapy and its development as a new treatment for inherited retinal diseases.